Home  >  News
Eppen_CellXpert_Feb25
Waters_Ebook_Dec24
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio

Our Bureau, Mumbai
Tuesday, December 31, 2024, 12:15 Hrs  [IST]

Global pharma major Lupin Limited announced the acquisition of Huminsulin in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India.
 
The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. There is a significant Indian population affected with diabetes for both type 1 and type 2 diabetes mellitus, where Insulin Human is prescribed for management along with other concomitant therapies.
 
“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” said Nilesh Gupta, managing director, Lupin.
 
Commenting on the acquisition, Rajeev Sibal, president – India region formulations, Lupin said, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”
 
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Avians_2025
Asia_Lab_Expo2025
chemexpoindia
ana-Lab-India_25
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram